Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-07-18

FDA Approved: LAMISIL AT — Supplemental Application (Karo Healthcare Inc.)

View source ↗

Summary

The FDA approved a supplemental application for LAMISIL AT (terbinafine hydrochloride) from Karo Healthcare Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LAMISIL AT (TERBINAFINE HYDROCHLORIDE)

Snippet

SUPPL AP for LAMISIL AT (TERBINAFINE HYDROCHLORIDE)